Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M

Tarsus Pharmaceuticals, Inc.

2024-Q1 EPS reported -$1.01 revenue$27,614,000

Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).
Net loss of $35.7M ($1.01 loss per share) vs $23.4M loss in Q1 2023.
SG&A expenses surged to $51.6M from $15.1M due to commercial launch costs.
Cash and marketable securities $298.5M as of Mar 31; secured $200M credit facility in Apr 2024 (drew $75M).
Secured commercial payer contracts covering ~18M lives on preferred status; broad coverage expected by end of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $27.6 million, net income $35.7 million, EPS $(1.01).

Period: first quarter ended March 31, 2024
Revenue: $27.6 million
Net income: $35.7 million
EPS: $(1.01)
Result: reported results

Exact text from the filing

million at the close, providing approximately $40 million net after the repayment of the previous facility First Quarter 2024 Financial Results • First quarter revenues were $27.6 million, driven primarily by $24.7 million in net product sales, and $2.9 million in license fees and collaboration revenue. • Cost of sales were $1.7 million, due to manufacturing

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-24-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.